17 results
8-K/A
EX-10.1
ARAV
Aravive Inc
28 Oct 22
Other Events
4:05pm
in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when … be true and correct in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect
8-K
EX-10.1
ARAV
Aravive Inc
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when … and correct in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all
8-K
EX-10.2
ARAV
Aravive Inc
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made … material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made
8-K
EX-5.1
ARAV
Aravive Inc
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
limitation, concepts of materiality, reasonableness, good faith and fair dealing) regardless of whether considered in a proceeding in equity or at law
8-K
EX-10.1
mzpv lz2n6
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
DEFA14A
150ifl
21 Mar 22
Additional proxy soliciting materials
4:05pm
8-K
j748ry
21 Mar 22
Other Events
4:05pm
8-K
mdun5t2yoz3z4updz
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
k0xq2h4p1a
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
ipr73
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
4ab vsl7xxerguuksit0
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
S-4
k4nwu7836bqo
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
S-4
EX-10.1
wylr53ak4h va0k
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
8-K
d74dh1a 7klxqz
6 Mar 15
Regulation FD Disclosure
12:00am
8-K
n6lhtpd57olcc
22 Sep 14
Regulation FD Disclosure
12:00am
8-K
y39s2120
23 Jun 14
Regulation FD Disclosure
12:00am
- Prev
- 1
- Next